Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

39 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and pharmacokinetics of plasma-derived mannose-binding lectin (MBL) substitution in children with chemotherapy-induced neutropaenia.
Frakking FN, Brouwer N, van de Wetering MD, Budde IK, Strengers PF, Huitema AD, Laursen I, Houen G, Caron HN, Dolman KM, Kuijpers TW. Frakking FN, et al. Among authors: strengers pf. Eur J Cancer. 2009 Mar;45(4):505-12. doi: 10.1016/j.ejca.2008.11.036. Epub 2008 Dec 31. Eur J Cancer. 2009. PMID: 19121580 Clinical Trial.
Treatment of hereditary angioedema with nanofiltered C1-esterase inhibitor concentrate (Cetor®): multi-center phase II and III studies to assess pharmacokinetics, clinical efficacy and safety.
Hofstra JJ, Kleine Budde I, van Twuyver E, Choi G, Levi M, Leebeek FW, de Monchy JG, Ypma PF, Keizer RJ, Huitema AD, Strengers PF. Hofstra JJ, et al. Among authors: strengers pf. Clin Immunol. 2012 Mar;142(3):280-90. doi: 10.1016/j.clim.2011.11.005. Epub 2011 Nov 16. Clin Immunol. 2012. PMID: 22197071 Clinical Trial.
Individualized dosing regimen for prothrombin complex concentrate more effective than standard treatment in the reversal of oral anticoagulant therapy: an open, prospective randomized controlled trial.
van Aart L, Eijkhout HW, Kamphuis JS, Dam M, Schattenkerk ME, Schouten TJ, Ploeger B, Strengers PF. van Aart L, et al. Among authors: strengers pf. Thromb Res. 2006;118(3):313-20. doi: 10.1016/j.thromres.2005.08.005. Epub 2005 Sep 21. Thromb Res. 2006. PMID: 16182346 Clinical Trial.
The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia. A randomized, double-blind, multicenter crossover trial.
Eijkhout HW, van Der Meer JW, Kallenberg CG, Weening RS, van Dissel JT, Sanders LA, Strengers PF, Nienhuis H, Schellekens PT; Inter-University Working Party for the Study of Immune Deficiencies. Eijkhout HW, et al. Among authors: strengers pf. Ann Intern Med. 2001 Aug 7;135(3):165-74. doi: 10.7326/0003-4819-135-3-200108070-00008. Ann Intern Med. 2001. PMID: 11487483 Clinical Trial.
An ultrapure plasma-derived monoclonal antibody-purified factor IX concentrate (Nonafact®), results of phase III and IV clinical studies.
Mauser-Bunschoten EP, Kleine Budde I, Lopaciuk S, Koopman MM, Van Der Meer FJ, Novàkovà IR, Ypma P, Van Der Linden PW, Windyga J, Strengers PF. Mauser-Bunschoten EP, et al. Among authors: strengers pf. Haemophilia. 2011 May;17(3):439-45. doi: 10.1111/j.1365-2516.2010.02453.x. Epub 2011 Mar 1. Haemophilia. 2011. PMID: 21362109 Clinical Trial.
39 results